cardiomegaly

Summary

Summary: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE, CONGESTIVE) or several forms of CARDIOMYOPATHIES.

Top Publications

  1. ncbi MicroRNA-133 controls cardiac hypertrophy
    Alessandra Carè
    Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore Sanita, 00161 Rome, Italy
    Nat Med 13:613-8. 2007
  2. ncbi Regulation of cardiac hypertrophy by intracellular signalling pathways
    Joerg Heineke
    Department of Pediatrics, University of Cincinnati, Children s Hospital Medical Center, Division of Molecular Cardiovascular Biology, 3333 Burnet Ave, Cincinnati, Ohio 45229, USA
    Nat Rev Mol Cell Biol 7:589-600. 2006
  3. ncbi The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress
    Atsuko Nakai
    Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita Osaka 565 0871, Japan
    Nat Med 13:619-24. 2007
  4. pmc MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice
    Thomas E Callis
    Carolina Cardiovascular Biology Center, University of North Carolina, Chapel Hill, North Carolina, USA
    J Clin Invest 119:2772-86. 2009
  5. ncbi A calcineurin-dependent transcriptional pathway for cardiac hypertrophy
    J D Molkentin
    Department of Molecular Biology and Oncology, The University of Texas Southwestern Medical Center at Dallas, 75225 9148, USA
    Cell 93:215-28. 1998
  6. pmc MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy?
    Yunhui Cheng
    Cardiovascular Research Laboratory, Vascular Biology Center and Department of Surgery, University of Tennessee Health Science Center, 956 Court Avenue, Memphis, TN 38163, USA
    Am J Pathol 170:1831-40. 2007
  7. ncbi Cardiac hypertrophy: the good, the bad, and the ugly
    N Frey
    Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9148, USA
    Annu Rev Physiol 65:45-79. 2003
  8. doi Cardiac plasticity
    Joseph A Hill
    Donald W Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX 75390 8573, USA
    N Engl J Med 358:1370-80. 2008
  9. pmc MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes
    Sadakatsu Ikeda
    Department of Cardiology, Children s Hospital Boston, Department of Genetics, Harvard Medical School, Boston, Massachusetts 021151, USA
    Mol Cell Biol 29:2193-204. 2009
  10. pmc Activating transcription factor 3 deficiency promotes cardiac hypertrophy, dysfunction, and fibrosis induced by pressure overload
    Heng Zhou
    Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China
    PLoS ONE 6:e26744. 2011

Detail Information

Publications348 found, 100 shown here

  1. ncbi MicroRNA-133 controls cardiac hypertrophy
    Alessandra Carè
    Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore Sanita, 00161 Rome, Italy
    Nat Med 13:613-8. 2007
    ..Our data show that miR-133, and possibly miR-1, are key regulators of cardiac hypertrophy, suggesting their therapeutic application in heart disease...
  2. ncbi Regulation of cardiac hypertrophy by intracellular signalling pathways
    Joerg Heineke
    Department of Pediatrics, University of Cincinnati, Children s Hospital Medical Center, Division of Molecular Cardiovascular Biology, 3333 Burnet Ave, Cincinnati, Ohio 45229, USA
    Nat Rev Mol Cell Biol 7:589-600. 2006
    ..Recent findings in genetically modified animal models implicate important intermediate signal-transduction pathways in the coordination of heart growth following physiological and pathological stimulation...
  3. ncbi The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress
    Atsuko Nakai
    Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita Osaka 565 0871, Japan
    Nat Med 13:619-24. 2007
    ....
  4. pmc MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice
    Thomas E Callis
    Carolina Cardiovascular Biology Center, University of North Carolina, Chapel Hill, North Carolina, USA
    J Clin Invest 119:2772-86. 2009
    ..Together, our studies uncover what we believe are novel miRNA-dependent mechanisms that modulate cardiac hypertrophy and electrical conduction...
  5. ncbi A calcineurin-dependent transcriptional pathway for cardiac hypertrophy
    J D Molkentin
    Department of Molecular Biology and Oncology, The University of Texas Southwestern Medical Center at Dallas, 75225 9148, USA
    Cell 93:215-28. 1998
    ..Pharmacologic inhibition of calcineurin activity blocks hypertrophy in vivo and in vitro. These results define a novel hypertrophic signaling pathway and suggest pharmacologic approaches to prevent cardiac hypertrophy and heart failure...
  6. pmc MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy?
    Yunhui Cheng
    Cardiovascular Research Laboratory, Vascular Biology Center and Department of Surgery, University of Tennessee Health Science Center, 956 Court Avenue, Memphis, TN 38163, USA
    Am J Pathol 170:1831-40. 2007
    ..miRNAs might be a new therapeutic target for cardiovascular diseases involving cardiac hypertrophy such as hypertension, ischemic heart disease, valvular diseases, and endocrine disorders...
  7. ncbi Cardiac hypertrophy: the good, the bad, and the ugly
    N Frey
    Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9148, USA
    Annu Rev Physiol 65:45-79. 2003
    ..In this review, we summarize recent insights into hypertrophic signaling and consider several novel antihypertrophic strategies...
  8. doi Cardiac plasticity
    Joseph A Hill
    Donald W Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX 75390 8573, USA
    N Engl J Med 358:1370-80. 2008
  9. pmc MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes
    Sadakatsu Ikeda
    Department of Cardiology, Children s Hospital Boston, Department of Genetics, Harvard Medical School, Boston, Massachusetts 021151, USA
    Mol Cell Biol 29:2193-204. 2009
    ..Our data indicate that miR-1 regulates cardiomyocyte growth responses by negatively regulating the calcium signaling components calmodulin, Mef2a, and Gata4...
  10. pmc Activating transcription factor 3 deficiency promotes cardiac hypertrophy, dysfunction, and fibrosis induced by pressure overload
    Heng Zhou
    Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China
    PLoS ONE 6:e26744. 2011
    ..Our results suggested that ATF3 plays a crucial role in the development of cardiac hypertrophy via negative regulation of the MEK-ERK1/2 and JNK pathways...
  11. ncbi Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy
    Chun Li Zhang
    Department of Molecular Biology, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas 75390, USA
    Cell 110:479-88. 2002
    ..mice lacking the class II HDAC, HDAC9, are sensitized to hypertrophic signals and exhibit stress-dependent cardiomegaly. Thus, class II HDACs act as signal-responsive suppressors of the transcriptional program governing cardiac ..
  12. ncbi Control of stress-dependent cardiac growth and gene expression by a microRNA
    Eva van Rooij
    Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9148, USA
    Science 316:575-9. 2007
    ..Thus, the alphaMHC gene, in addition to encoding a major cardiac contractile protein, regulates cardiac growth and gene expression in response to stress and hormonal signaling through miR-208...
  13. ncbi Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies
    Bianca C Bernardo
    Cardiac Hypertrophy Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
    Pharmacol Ther 128:191-227. 2010
    ..Finally, we explore how knowledge of molecular mechanisms underlying pathological and physiological hypertrophy may influence therapeutic strategies for the treatment of cardiovascular disease and heart failure...
  14. ncbi Oxidative stress and cardiac hypertrophy: a review
    Subir Kumar Maulik
    Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India
    Toxicol Mech Methods 22:359-66. 2012
    ..All these evidences strongly provide support to beneficial role of drugs which selectively interfere with the generation of free radicals or augment endogenous antioxidants in cardiac hypertrophy...
  15. ncbi Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy
    Ichiro Manabe
    Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan
    Circ Res 91:1103-13. 2002
    ..A particular focus is the recent progress toward our understanding of the transcriptional regulatory mechanisms involved...
  16. pmc Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats
    Giselle C Melendez
    Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, SC 29208, USA
    Hypertension 56:225-31. 2010
    ..These novel observations demonstrate that IL-6 induces a myocardial phenotype almost identical to that of the hypertensive heart, identifying IL-6 as potentially important in this remodeling process...
  17. pmc Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling
    Qinghang Liu
    Department of Physiology and Biophysics, University of Washington, Seattle, USA
    Circ Res 110:1077-86. 2012
    ....
  18. ncbi MicroRNAs: novel regulators in cardiac development and disease
    Thomas Thum
    Medizinische Klinik und Poliklinik I, Universitatsklinikum, Julius Maximilians Universitat, Josef Schneider Street 2, D 97080 Wurzburg, Germany
    Cardiovasc Res 79:562-70. 2008
    ..Finally, we focus on the development and use of miRNA antagonists (antagomirs) to target miRNAs in vivo, which may translate into novel therapeutic strategies for heart disease in the future...
  19. ncbi An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy
    Peiyong Zhai
    Cardiovascular Research Institute, Department of Cell Biology and Molecular Medicine, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark 07103, USA
    Circ Res 99:528-36. 2006
    ..The YIPP motif in the AT(1)R plays an important role in mediating cardiac hypertrophy in vivo...
  20. ncbi Role of oxidative stress in myocardial hypertrophy and failure
    Douglas B Sawyer
    Cardiovascular Medicine Section, Department of Medicine, Boston, MA, USA
    J Mol Cell Cardiol 34:379-88. 2002
  21. ncbi Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms
    Stefan Hein
    Kerckhoff Clinic, Department of Thoracic and Cardiovascular Surgery, Bad Nauheim, Germany
    Circulation 107:984-91. 2003
    ....
  22. ncbi Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis
    Ken ichiro Okada
    Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    Circulation 110:705-12. 2004
    ..The ER responds to stress by upregulating ER chaperones, but prolonged and/or excess ER stress leads to apoptosis. However, the potential role of ER stress in pathophysiological hearts remains unclear...
  23. pmc TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II
    Jo El J Schultz
    Department of Molecular Genetics, Biochemistry, and Microbiology, Cincinnati College of Medicine, 231 Albert Sabin Way, ML 0575, Cincinnati, OH 45267, USA
    J Clin Invest 109:787-96. 2002
    ..These results indicate that TGF-beta1 is an important mediator of the hypertrophic growth response of the heart to Ang II...
  24. ncbi Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart
    Esther E Creemers
    Heart Failure Research Center, Academic Medical Center, Meibergdreef 15, Room L2 108 3, 1105 AZ Amsterdam, The Netherlands
    Cardiovasc Res 89:265-72. 2011
    ..Finally, we will discuss the recent discovery that miRNAs importantly regulate cardiac fibrosis...
  25. pmc MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts
    Scot J Matkovich
    Center for Pharmacogenomics, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Circ Res 106:166-75. 2010
    ..Because miR-133a levels decrease during reactive cardiac hypertrophy, some have considered that restoring miR-133a levels could suppress hypertrophic remodeling...
  26. ncbi The role of natriuretic peptides in cardioprotection
    Toshio Nishikimi
    Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Mibu, Tochigi 321 0293, Japan
    Cardiovasc Res 69:318-28. 2006
    ..In a clinical setting, human recombinant ANP and BNP may be used for a therapy of heart failure; however, further evaluation is required in the future...
  27. pmc A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy
    Takaaki Senbonmatsu
    Departments of Biochemistry, Pharmacology, Pathology and Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 0146, USA
    EMBO J 22:6471-82. 2003
    ..PLZF is expressed robustly in the heart in contrast to many other tissues. This cardiac selective pathway involving AT(2), PLZF and p85 alpha PI3K may explain the absence of a cardiac hypertrophic response in AT(2) gene-deleted mice...
  28. pmc Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure
    Dao Fu Dai
    Department of Pathology, University of Washington, 1959 Pacific Ave NE, Seattle, WA 98195, USA
    Circ Res 108:837-46. 2011
    ..Mitochondrial dysfunction has been implicated in several cardiovascular diseases; however, the roles of mitochondrial oxidative stress and DNA damage in hypertensive cardiomyopathy are not well understood...
  29. ncbi Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophy
    Horacio E Cingolani
    Centro de Investigaciones Cardiovasculares, Facultad de Ciencias Medicas, Universidad Nacional de La Plata, Calle 60 y 120, 1900 La Plata, Argentina
    Circulation 115:1090-100. 2007
  30. ncbi Role of oxidative stress in cardiac hypertrophy and remodeling
    Eiki Takimoto
    Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Hypertension 49:241-8. 2007
  31. ncbi Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7)
    Justin L Grobe
    Department of Pharmacodynamics, University of Florida, Gainesville, FL 32610 0487, USA
    Am J Physiol Heart Circ Physiol 292:H736-42. 2007
    ....
  32. pmc Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice
    Rusty L Montgomery
    Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Clin Invest 118:3588-97. 2008
    ..These findings reveal a unique role for Hdac3 in maintenance of cardiac function and regulation of myocardial energy metabolism...
  33. pmc Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy
    Dian J Cao
    Department of Internal Medicine Cardiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Proc Natl Acad Sci U S A 108:4123-8. 2011
    ..Together, these data implicate autophagy as an obligatory element in pathological cardiac remodeling and point to HDAC1/2 as required effectors. Also, these data reveal autophagy as a previously unknown target of HDAC inhibitor therapy...
  34. pmc miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy
    Zhiqiang Lin
    Division of Cardiovascular Research, National Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China
    Proc Natl Acad Sci U S A 106:12103-8. 2009
    ..Its translation could be suppressed by miR-23a. Our data provide a model in which the miRNA expression is regulated by the hypertrophic transcriptional factor...
  35. pmc Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice
    S Engelhardt
    Institut fur Pharmakologie, Universitat Wurzburg, Versbacher Strasse 9, 97078 Wurzburg, Germany
    Proc Natl Acad Sci U S A 96:7059-64. 1999
    ..We conclude that overexpression of beta1-adrenergic receptors in the heart may lead to a short-lived improvement of cardiac function, but that increased beta1-adrenergic receptor signalling is ultimately detrimental...
  36. ncbi Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding
    Hae Jin Kee
    Department of Pharmacology, Research Institute of Medical Sciences and Medical Research Center for Gene Regulation, Chonnam National University Medical School, Gwangju, South Korea
    Circulation 113:51-9. 2006
    ..We tested the effects of several HDAC inhibitors, including a class I HDAC-selective inhibitor, SK-7041, on cardiac hypertrophy induced by angiotensin II (Ang II) treatment or aortic banding (AB)...
  37. ncbi Molecular regulation of cardiac hypertrophy
    Sean P Barry
    Medical Molecular Biology Unit, Institute of Child Health, University College London, 30 Guilford Street, London WC1N IEH, United Kingdom
    Int J Biochem Cell Biol 40:2023-39. 2008
    ..The challenge will be translating this knowledge into potential pharmacological therapies for the treatment of cardiac pathologies...
  38. pmc Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5
    Rick B Vega
    Department of Molecular Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9148, USA
    Mol Cell Biol 24:8374-85. 2004
    ....
  39. ncbi GATA transcription factors in the developing and adult heart
    Sampsa Pikkarainen
    Department of Pharmacology and Toxicology, Faculty of Medicine, Biocenter Oulu, University of Oulu, P O Box 5000, FIN 90014 Oulu, Finland
    Cardiovasc Res 63:196-207. 2004
    ..The present review discusses current evidence of the role and regulation of GATA transcription factors in the heart, with an emphasis in the GATA-4 and development of cardiac hypertrophy...
  40. pmc Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats
    Pal Pacher
    Section on Oxidative Stress Tissue Injury, Laboratories of Physiological Studies, National Institutes of Health NIAAA, 5625 Fishers Lane, MSC 9413, Bethesda, Maryland 20892 9413, USA
    Nat Protoc 3:1422-34. 2008
    ..The completion of the protocol takes 1-4 h (depending on the experimental design/end points)...
  41. pmc Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart
    E D Abel
    Division of Endocrinology and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    J Clin Invest 104:1703-14. 1999
    ..Basal and isoproterenol-stimulated isovolumic contractile performance was preserved. Thus, selective ablation of GLUT4 in the heart initiates a series of events that results in compensated cardiac hypertrophy...
  42. pmc Adiponectin-mediated modulation of hypertrophic signals in the heart
    Rei Shibata
    Molecular Cardiology Whitaker Cardiovascular Institute, Boston University School of Medicine, 715 Albany Street, W611, Boston, Massachusetts 02118, USA
    Nat Med 10:1384-9. 2004
    ..Adiponectin may have utility for the treatment of hypertrophic cardiomyopathy associated with diabetes and other obesity-related diseases...
  43. ncbi Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface
    Timothy A McKinsey
    Gilead Colorado, Inc, 7575 West 103rd Avenue, Westminster, Colorado 80021, USA
    Nat Rev Drug Discov 6:617-35. 2007
    ....
  44. ncbi Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways
    Michael A Crackower
    IMBA, Institute for Molecular Biotechnology of the Austrian Academy of Sciences, c o Dr Bohr Gasse 7, A 1030, Vienna, Austria
    Cell 110:737-49. 2002
    ..These data show that PTEN has an important in vivo role in cardiomyocyte hypertrophy and GPCR signaling and identify a function for the PTEN-PI3Kgamma pathway in the modulation of heart muscle contractility...
  45. ncbi Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype
    J Sadoshima
    Molecular Medicine Division, Beth Israel Hospital, Boston, Mass 02215
    Circ Res 73:413-23. 1993
    ....
  46. ncbi Molecular targets and regulators of cardiac hypertrophy
    Agrawal Rohini
    JSS College of Pharmacy 1 Off campus of JSS University, Mysore, Ooty, Tamilnadu, India ahuja
    Pharmacol Res 61:269-80. 2010
    ..The purpose of this review is to provide the current knowledge about the molecular pathogenesis of cardiac hypertrophy, with special emphasis on novel researches and investigations...
  47. ncbi Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade
    Scott E Woodman
    Department of Molecular Pharmacology, Division of Hormone Dependent Tumor Biology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    J Biol Chem 277:38988-97. 2002
    ..Taken together, our data argue that loss of Cav-3 expression is sufficient to induce a molecular program leading to cardiac myocyte hypertrophy and cardiomyopathy...
  48. ncbi Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy
    Benjamin J Wilkins
    Division of Molecular Cardiovascular Biology, Department of Pediatrics, Children s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, Ohio 45229 3039, USA
    Circ Res 94:110-8. 2004
    ....
  49. pmc Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure
    Mahesh P Gupta
    Department of Surgery, Basic Science Division, MC5040, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    J Mol Cell Cardiol 43:388-403. 2007
    ..This article reviews the published data describing the role of myosin isoforms in the heart and highlighting the importance of various factors shown to influence myosin isofrom shift during physiology and disease states of the heart...
  50. ncbi Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats
    Robson A S Santos
    Laboratory of Hypertension, Department of Physiology and Biophysics, Biological Sciences Institute, Federal University of Minas Gerais, Belo Horizonte, MG, 31270 901 Brazil
    Physiol Genomics 17:292-9. 2004
    ..These results support a cardioprotective role for circulating ANG-(1-7) and provide a novel tool for evaluating the functional role of ANG-(1-7)...
  51. pmc TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy
    Naoya Onohara
    Department of Pharmacology and Toxicology, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi ku, Fukuoka
    EMBO J 25:5305-16. 2006
    ..These data suggest that DAG-induced Ca(2+) signaling pathway through TRPC3 and TRPC6 is essential for Ang II-induced NFAT activation and cardiac hypertrophy...
  52. ncbi GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation
    Jian Xu
    Department of Pediatrics, University of Cincinnati, Division of Molecular Cardiovascular Biology, Children s Hospital Medical Center, Ohio 45229 3039, USA
    Circ Res 98:342-50. 2006
    ..These results identify GDF15 as a novel autocrine/endocrine factor that antagonizes the hypertrophic response and loss of ventricular performance, possibly through a mechanism involving SMAD proteins...
  53. pmc Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo
    Nicole H Purcell
    Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    Proc Natl Acad Sci U S A 104:14074-9. 2007
    ..Thus, ERK1/2 signaling is not required for mediating physiologic or pathologic cardiac hypertrophy in vivo, although it does play a protective role in response to pathologic stimuli...
  54. ncbi Rapamycin attenuates load-induced cardiac hypertrophy in mice
    Tetsuo Shioi
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, Mass 02215, USA
    Circulation 107:1664-70. 2003
    ..The mammalian target of rapamycin (mTOR) is a component of the insulin-phosphoinositide 3-kinase pathway, which is known to play a critical role in the determination of cell, organ, and body size...
  55. ncbi The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature
    Hannerieke M P Van den Hout
    Divison of Metabolic Diseases and Genetics, Department of Pediatrics, Erasmus Medical Center Sophia Children s Hospital, Rotterdam, The Netherlands
    Pediatrics 112:332-40. 2003
    ..Current developments toward enzyme replacement therapy are promising. The aim of our study is to delineate the natural course of the disease to verify endpoints of clinical studies...
  56. ncbi Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system
    Matthew C Zimmerman
    Department of Anatomy and Cell Biology, The University of Iowa, Roy J and Lucille A Carver College of Medicine, Iowa City 52242, USA
    Circ Res 95:210-6. 2004
    ..These data suggest that increased intracellular O2*- production in the SFO is critical in the development of Ang II-induced hypertension...
  57. pmc Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy
    Yongli Kong
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 8573, USA
    Circulation 113:2579-88. 2006
    ..Thus, HDAC inhibitors hold promise as potential therapeutic agents in hypertrophic heart disease...
  58. ncbi Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload
    Julie R McMullen
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, Mass 02215, USA
    Circulation 109:3050-5. 2004
    ..We recently reported that administration of rapamycin before exposure to ascending aortic constriction significantly attenuated the load-induced increase in heart weight by approximately 70%...
  59. ncbi Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy
    De Li Dong
    Department of Pharmacology, Harbin Medical University, Baojian Rd 157, Harbin 150081, Heilongjiang Province, People s Republic of China
    Hypertension 55:946-52. 2010
    ..Our data show that reciprocal repression between miR-133 and calcineurin regulates cardiac hypertrophy...
  60. ncbi Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy
    Lennart Suckau
    Department of Cardiology and Pneumology, Charite University Medicine Berlin, Germany
    Circulation 119:1241-52. 2009
    ..Whereas gene therapy rests on recombinant protein expression as its basic principle, RNAi therapy uses regulatory RNAs to achieve its effect...
  61. ncbi Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1)
    Stephan Rosenkranz
    Klinik III fur Innere Medizin, Universitat zu Koln, 50924 Köln, Germany
    Am J Physiol Heart Circ Physiol 283:H1253-62. 2002
    ....
  62. ncbi Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure
    Julie R McMullen
    Baker Heart Research Institute, Melbourne, Victoria 8008, Australia
    Clin Exp Pharmacol Physiol 34:255-62. 2007
    ..4. The present review discusses the possibility of targeting cardioprotective signalling pathways and genes activated in the athlete's heart to treat or prevent heart failure...
  63. pmc Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex
    Hui Hua Li
    Carolina Cardiovascular Biology Center, University of North Carolina at Chapel Hill, NC 27599 7126, USA
    J Clin Invest 114:1058-71. 2004
    ....
  64. ncbi Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II
    K Nakamura
    Department of Cardiovascular Medicine, Okayama University Medical School, Japan
    Circulation 98:794-9. 1998
    ..Signal transduction pathways of those factors are implicated in reactive oxygen intermediates (ROIs). Therefore, we hypothesized that TNF-alpha and Ang II might cause myocyte hypertrophy via the generation of ROIs...
  65. pmc HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats
    Jeffrey P Cardinale
    Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA
    Hypertension 56:437-44. 2010
    ....
  66. pmc Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload
    Hongliang Li
    Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China
    Proc Natl Acad Sci U S A 107:13818-23. 2010
    ..These studies indicate that Rgs5 protein is a crucial component of the signaling pathway involved in cardiac remodeling and heart failure...
  67. ncbi Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors
    Christopher L Antos
    Department of Molecular Biology, The University of Texas, Southwestern Medical Center at Dallas, Dallas, Texas 75390 9148, USA
    J Biol Chem 278:28930-7. 2003
    ..HDAC inhibitors are currently being tested in clinical trials as anti-cancer agents. Our results suggest that these inhibitors may also hold promising clinical value as therapeutics for cardiac hypertrophy and heart failure...
  68. pmc Cardiac hypertrophy and thyroid hormone signaling
    Wolfgang Dillmann
    University of California, San Diego, USA
    Heart Fail Rev 15:125-32. 2010
    ..The failing heart may develop a "hypothyroid" status contributing to diminished cardiac contractile function...
  69. ncbi Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure
    Tomoe Y Nakamura
    Department of Molecular Physiology, National Cardiovascular Center Research Institute, Suita, Osaka 565 8565, Japan
    Circ Res 103:891-9. 2008
    ..We conclude that activation of NHE1 is sufficient to initiate cardiac hypertrophy and heart failure mainly through activation of CaMKII-histone deacetylase pathway...
  70. pmc NFATc4 is negatively regulated in miR-133a-mediated cardiomyocyte hypertrophic repression
    Qi Li
    Center for Molecular Development and Disease, Institute of Biosciences and Technology, Texas A and M Health Science Center, 2121 W Holcombe Blvd, Houston, TX 77030, USA
    Am J Physiol Heart Circ Physiol 298:H1340-7. 2010
    ..Application of miR-133a had no apparent effect on NFATc4 nuclear localization. We conclude that the negative regulation of NFATc4 expression contributes to miR-133a-mediated hypertrophic repression...
  71. pmc Protein kinase cascades in the regulation of cardiac hypertrophy
    Gerald W Dorn
    Heart and Vascular Center, Medical Center, University of Cincinnati, Cincinnati, Ohio 45267 0542, USA
    J Clin Invest 115:527-37. 2005
    ..Here we review recent developments in the area of these cardiotrophic kinases, highlighting the utility of animal models that are helping to identify molecular targets in the human condition...
  72. ncbi Roles of cardiac transcription factors in cardiac hypertrophy
    Hiroshi Akazawa
    Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, 1 8 1 Inohana, Chuo Ku, Chiba 260 8670, Japan
    Circ Res 92:1079-88. 2003
    ..In this review, the regulation of a cardiac gene program by cardiac transcription factors is summarized, with an emphasis on their potential role in the generation of cardiac hypertrophy...
  73. pmc The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice
    O F Bueno
    Department of Pediatrics, University of Cincinnati, Division of Molecular Cardiovascular Biology, Children s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229 3039, USA
    EMBO J 19:6341-50. 2000
    ..The results of the present study indicate that the MEK1-ERK1/2 signaling pathway stimulates a physiologic hypertrophy response associated with augmented cardiac function and partial resistance to apoptotsis...
  74. ncbi Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy
    Qing Li
    Key Laboratory of Stem Cell Biology and Laboratory of Nucleic Acid and Molecular Medicine, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    J Cell Sci 123:2444-52. 2010
    ....
  75. ncbi Cardiac hypertrophy is not a required compensatory response to short-term pressure overload
    J A Hill
    Division of Cardiovascular Diseases, Department of Internal Medicine, Department of Veterans Affairs, University of Iowa College of Medicine, Iowa City 52242 1081, USA
    Circulation 101:2863-9. 2000
    ..Cardiac hypertrophy is considered a necessary compensatory response to sustained elevations of left ventricular (LV) wall stress...
  76. ncbi Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling
    Paula A da Costa Martins
    Department of Medical Physiology, University Medical Center Utrecht, Utrecht, Netherlands
    Circulation 118:1567-76. 2008
    ..Dicer, an RNAse III endonuclease critical for processing of pre-microRNAs (miRNAs) into mature 22-nucleotide miRNAs, has proven a useful target to dissect the significance of miRNAs biogenesis in mammalian biology...
  77. ncbi Sympathetic alpha(2)-adrenoceptors prevent cardiac hypertrophy and fibrosis in mice at baseline but not after chronic pressure overload
    Ralf Gilsbach
    Institute of Experimental and Clinical Pharmacology and Toxicology, University of Freiburg, Albertstrasse 25, Freiburg 79104, Germany
    Cardiovasc Res 86:432-42. 2010
    ..The aim of this study was to define the physiological and pharmacological role of alpha(2A)-adrenoceptors in adrenergic vs. non-adrenergic cells at baseline and during sympathetic stress...
  78. ncbi Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy
    Jaya Krishnan
    Institute of Cell Biology and Competence Center for Systems Physiology and Metabolic Diseases, ETH Zurich, Zurich, Switzerland
    Cell Metab 9:512-24. 2009
    ..We propose a model in which activation of the HIF1alpha-PPARgamma axis by pathologic stress underlies key changes in cell metabolism that are characteristic of and contribute to common forms of heart disease...
  79. pmc Akt and MAPK signaling mediate pregnancy-induced cardiac adaptation
    Eunhee Chung
    Department of Molecular, Cellular, and Developmental Biology and Biofrontiers Institute, University of Colorado, Boulder, Colorado 80309 0347, USA
    J Appl Physiol (1985) 112:1564-75. 2012
    ..Inhibition of MEK1 effectively blocked progesterone-induced cellular hypertrophy. Taken together, our study demonstrates that pregnancy-induced cardiac hypertrophy is mediated by activation of Akt and ERK1/2 pathways...
  80. ncbi Akt signaling mediates postnatal heart growth in response to insulin and nutritional status
    Ichiro Shiojima
    Molecular Cardiology Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Biol Chem 277:37670-7. 2002
    ....
  81. ncbi Activation of IP prostanoid receptors prevents cardiomyocyte hypertrophy via cAMP-dependent signaling
    Rebecca H Ritchie
    Howard Florey Institute, Melbourne, Victoria 8008, Australia
    Am J Physiol Heart Circ Physiol 287:H1179-85. 2004
    ..01, n = 5). Activation of IP receptors thus represents a novel approach to prevention of hypertrophy, and this effect is linked to cAMP-dependent signaling...
  82. ncbi Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies
    Oleg Tarnavski
    Cardiovascular Research Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Physiol Genomics 16:349-60. 2004
    ..The cardiac surgical techniques described have been, and will continue to be, important for elucidating the molecular mechanisms of cardiac hypertrophy and failure with high-throughput technology...
  83. ncbi A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy
    Kristina Lorenz
    Institute of Pharmacology and Toxicology, University of Wurzburg, Versbacher Strasse 9, Wurzburg, Germany
    Nat Med 15:75-83. 2009
    ..We propose that specific phosphorylation events on ERK1/2 integrate differing upstream signals (Raf1-MEK1/2 or G protein-coupled receptor-G(q)) to induce cardiac hypertrophy...
  84. ncbi Overexpression of junctate induces cardiac hypertrophy and arrhythmia via altered calcium handling
    Chang Soo Hong
    Department of Biological Science, College of Natural Sciences, Daegu University, Gyeongsan, South Korea
    J Mol Cell Cardiol 44:672-82. 2008
    ..Junctate-1 in the heart is closely linked to the homeostasis of E-C coupling proteins and a sustained increase of junctate-1 expression leads to a severe cardiac remodeling and arrhythmias...
  85. ncbi Dysregulation of the TSC-mTOR pathway in human disease
    Ken Inoki
    Life Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, USA
    Nat Genet 37:19-24. 2005
    ....
  86. ncbi The expression of mRNA of cytokines and of extracellular matrix proteins in triiodothyronine-treated rat hearts
    Barbara Ziegelhöffer-Mihalovicová
    Carl Ludwig Institute of Physiology, University of Leipzig, Leipzig, Germany
    Mol Cell Biochem 247:61-8. 2003
    ..The moderate increase in mRNA for ECMP and MMP may be attributed more to the increasing mass of the ventricles with the accompanying remodelling of the ECM than to increased fibrosis...
  87. ncbi Increased expression and intramitochondrial translocation of cyclophilin-D associates with increased vulnerability of the permeability transition pore to stress-induced opening during compensated ventricular hypertrophy
    Jimmy Matas
    Département de Kinésiologie, Universite de Montreal, C P 6128, Succursale Centre Ville, Montreal, Quebec, Canada H3C 3J7
    J Mol Cell Cardiol 46:420-30. 2009
    ....
  88. ncbi Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP
    Anke C Rosenkranz
    Howard Florey Institute, C The University of Melbourne, Parkville, VIC 3010, Australia
    Cardiovasc Res 57:515-22. 2003
    ..However, whether this effect is retained in the adult phenotype or if other members of the natriuretic peptide family exhibit similar antihypertrophic properties, has not been elucidated...
  89. ncbi The transcriptional coactivator CAMTA2 stimulates cardiac growth by opposing class II histone deacetylases
    Kunhua Song
    Department of Molecular Biology, The University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Blvd, Dallas, TX 75390, USA
    Cell 125:453-66. 2006
    ..These findings reveal a transcriptional regulatory mechanism that modulates cardiac growth and gene expression by linking hypertrophic signals to the cardiac genome...
  90. ncbi RGS4 reduces contractile dysfunction and hypertrophic gene induction in Galpha q overexpressing mice
    J H Rogers
    Center for Cardiovascular Research, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
    J Mol Cell Cardiol 33:209-18. 2001
    ..These studies establish for the first time a role for RGS4 as a GAP for Galpha q in the in vivo heart, and demonstrate that its regulated expression can have pathophysiologic consequences...
  91. pmc TRPC channels are necessary mediators of pathologic cardiac hypertrophy
    Xu Wu
    Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA
    Proc Natl Acad Sci U S A 107:7000-5. 2010
    ..Thus, TRPC channels are necessary mediators of pathologic cardiac hypertrophy, in part through a calcineurin-NFAT signaling pathway...
  92. pmc Signaling mechanisms in thyroid hormone-induced cardiac hypertrophy
    Kaie Ojamaa
    The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA
    Vascul Pharmacol 52:113-9. 2010
    ..The present review examines these molecular mechanisms and intracellular signaling pathways activated in thyroid hormone-induced cardiac hypertrophy that support its therapeutic potential in the treatment of heart disease...
  93. pmc Mammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats
    Will Soesanto
    College of Health, University of Utah, Salt Lake City, UT 84112, USA
    Hypertension 54:1321-7. 2009
    ..These data show that mammalian target of rapamycin is required for the development of cardiac hypertrophy evoked by rising blood pressure in SHRs...
  94. pmc Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy
    Oliver Drews
    School of Medicine, University of California Los Angeles, 675 Charles E Young Drive, Los Angeles, CA 90095 1760, USA
    Circ Res 107:1094-101. 2010
    ..Our recent investigations identified heterogeneous subpopulations of proteasome complexes in the heart and implicated multiple mechanisms for their regulation...
  95. ncbi S100A4 is upregulated in injured myocardium and promotes growth and survival of cardiac myocytes
    Mikael Schneider
    The Laboratory of Molecular and Cellular Cardiology, The Danish National Research Foundation Centre for Cardiac Arrhythmia, Department of Medicine B, H S Rigshospitalet, Copenhagen University Hospital, Denmark
    Cardiovasc Res 75:40-50. 2007
    ..We therefore hypothesized that S100A4 could play a supportive role in the injured heart...
  96. ncbi The nonpeptide AVE0991 attenuates myocardial hypertrophy as induced by angiotensin II through downregulation of transforming growth factor-beta1/Smad2 expression
    Jian gui He
    Department of Cardiology, First Affiliated Hospital of Sun Yat sen University, Guangzhou, PR China
    Heart Vessels 25:438-43. 2010
    ..These results suggested that AVE0991 prevented AngII-inducing myocardial hypertrophy in a dose-dependent fashion, a process that may be associated with the inhibition of TGF-beta1/Smad2 signaling...
  97. ncbi L-Thyroxine activates Akt signaling in the heart
    James A Kuzman
    School of Medicine, University of South Dakota, Cardiovascular Research Institute South Dakota Health Research Foundation, 1100 East 21st Street, Sioux Falls, SD 57105, USA
    J Mol Cell Cardiol 39:251-8. 2005
    ..In conclusion, activation of the Akt signaling pathway may contribute to the effects of TH on the heart. While this pathway is clearly activated, further work is needed to determine whether this is via a genomic or non-genomic mechanism...
  98. pmc Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy
    E Dale Abel
    Division of Endocrinology, Metabolism and Diabetes, and Program in Molecular Medicine, University of Utah School of Medicine, 15 North 2030 East, Bldg 533, Rm 3110B, Salt Lake City, UT 84112, USA
    Cardiovasc Res 90:234-42. 2011
    ..We suggest that mitochondrial adaptations to pathological and physiological hypertrophy are distinct, and we shall review potential mechanisms that might account for these differences...
  99. ncbi Simvastatin inhibits angiotensin II-induced cardiac cell hypertrophy: role of Homer 1a
    Wan Gang Guo
    Department of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi an, China
    Clin Exp Pharmacol Physiol 37:40-5. 2010
    ..5. These results suggest a possible role for Homer 1a in inhibiting cardiac hypertrophy perhaps in part through inhibition of ERK1/2 activation...
  100. ncbi Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro
    J Sadoshima
    Molecular Medicine Division, Beth Israel Hospital, Boston, Massachusetts
    Cell 75:977-84. 1993
    ..The results not only provide direct evidence for the autocrine mechanism in load-induced growth of cardiac muscle cells, but also define the pathophysiological role of the local (cardiac) renin-angiotensin system...
  101. ncbi Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy
    Eva van Rooij
    Department of Cardiology, Cardiovascular Research Institute Maastricht, University Hospital, P Debyelaan 25, The Netherlands
    J Biol Chem 277:48617-26. 2002
    ..These results indicate that multiple NFAT isoforms are expressed in cardiomyocytes where they function as necessary transducers of calcineurin in facilitating cardiomyocyte hypertrophy...

Research Grants65

  1. 2005 NNFF Consortium for NF1, NF2 and Schwannomatosis
    Jonathan Epstein; Fiscal Year: 2005
    ....
  2. Identification and Validation of Alcohol Biomarker Signatures by Proteomics
    Emanuel Rubin; Fiscal Year: 2010
    ..Early diagnosis of this condition by specific biomarkers will offer the opportunity for treatment and prevention of heart enlargement, congestive heart failure and death. ..
  3. Nuclear magnetic Tirho relaxation in acute and chronic myocardial infarctions
    Walter R T Witschey; Fiscal Year: 2013
    ..This training will prepare Dr. Witschey to achieve his career goals to advance our understanding and treatment of cardiac disease through novel and interdisciplinary techniques combined with basic science research. ..
  4. EFFECT OF CARBON MONOXIDE ON THE DEVELOPING HEART
    David Penney; Fiscal Year: 1980
    ..Studies in my laboratory and by others show that cardiomegaly is more dramatic in the young than the old...
  5. HIGH-RESOLUTION IMAGE PROCESSING WORKSTATION
    Kunio Doi; Fiscal Year: 1992
    ..detection of various abnormalities in the chest, due to interstitial disease, lung cancer, pneumothorax, and cardiomegaly. The mammography project of Dr. Giger, in collaboration with Drs...
  6. Metabolic enzyme activity mediating myocardial stunning
    E Lewandowski; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  7. Calpains as Mediators of Cardiac Ischemic Injury
    Gerald W Dorn; Fiscal Year: 2010
    ..Collectively, these studies will apply state-of-the-art techniques for in vivo genetic manipulation, microphysiologic analysis, and biochemical assessment to achieve insight into the roles of myocardial calpains in health and disease. ..
  8. CALMODULIN KINASE II AND EARLY AFTERDEPOLARIZATIONS
    Mark Anderson; Fiscal Year: 2007
    ..unreadable] [unreadable] Understanding these molecular mechanisms for Ca2+/CaM-dependent ICa facilitation will likely be necessary to develop improved therapies for TdP. [unreadable] [unreadable]..
  9. MAGNETIC RESONANCE CARDIAC C13FLUX AND METABOLIC RATE
    E Lewandowski; Fiscal Year: 2001
    ..The long range objective is the ultimate use of C13 NMR to assess the activity and expression of these mitochondrial proteins that regulate metabolic flux in intact and in vivo organs during development and disease. ..
  10. PHOSPHOLIPASE C AND CARDIAC HYPERTROPHY
    GERALD DORN; Fiscal Year: 2005
    ..abstract_text> ..
  11. PAX3 REGULATION OF CARDIAC CONOTRUNCAL DEVELOPMENT
    Jonathan Epstein; Fiscal Year: 2008
    ..Aim 3 examines the role of neural crest during development of the conduction system, and specifically examines Pax3 regulation of DCT. [unreadable] [unreadable]..
  12. Molecular basis of vascular heterogenity and function
    Jonathan Epstein; Fiscal Year: 2008
    ..abstract_text> ..
  13. LBX2 AND UROGENITAL DEVELOPMENT
    Jonathan Epstein; Fiscal Year: 2002
    ....
  14. Proteome Mapping of Heart Failure in Aging
    MARVIN BOLUYT; Fiscal Year: 2005
    ..Identification of proteins involved in aldosterone signaling will lead to the development of new hypotheses for future grant proposals addressing their roles in the development of heart failure in the elderly. ..
  15. Role of Acetaldehyde in Alcoholic Cardiomyopathy
    Jun Ren; Fiscal Year: 2008
    ..Our long-term goal is to establish the toxic mechanism of acetaldehyde in the development of alcoholic cardiomyopathy so that prevention and treatment can be optimized [unreadable] [unreadable]..
  16. Oxidative Stress and Heart Failure by Copper Restriction
    Y James Kang; Fiscal Year: 2010
    ..Therefore, Cu supplementation is not an appropriate approach to rescue diabetic cardiomyopathy. ..
  17. Apoptosis inducing factor in cardiac apoptosis
    Peter M Kang; Fiscal Year: 2010
    ..We will then explore a mechanism and a strategy for inhibiting AIF activation using PARP-1 inhibition in I/R-induced cardiac apoptosis in vivo. ..
  18. PHOSPHOINOSITIDE-3 KINASE IN CARDIAC HYPERTROPHY
    Peter Kang; Fiscal Year: 2004
    ..These studies will lead to a better understanding of the role of the PI3K pathway in determining the heart and myocyte size in physiological and pathological conditions in vivo. ..
  19. METALLOTHIONEIN AND ADRIAMYCIN CARDIOTOXICITY
    Y Kang; Fiscal Year: 2006
    ..abstract_text> ..
  20. Control of Cardiac Gene Expression Through Regulated Transcriptional Coactivators
    Eric N Olson; Fiscal Year: 2010
    ..abstract_text> ..
  21. Calcineurin-Mediated Regulation of Cardiac Ca2+ Channel
    Joseph Hill; Fiscal Year: 2009
    ..In Aim 4, we will determine whether the mechanisms of calcineurin regulation of Ca2+ channel expression and function examined in Aims 1-3 occur in a clinically relevant, in vivo model of hypertrophy. ..
  22. Cardiac Hypertrophy Due to Oxidative Stress Insulin
    Thunder Jalili; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  23. SUMMER RESEARCH PROGRAM FOR MINORITY MEDICAL STUDENTS
    Donald Menick; Fiscal Year: 2008
    ....
  24. Developmental regulation of cardiac gene expression
    Anthony Azakie; Fiscal Year: 2007
    ..An understanding of the transcriptional mechanisms that control cardiogenesis may also elucidate the molecular pathogenesis of various congenital heart defects and cardiomyopathies. ..
  25. Glucolipotoxicity and Cardiac Dysfunction in Obesity
    Heinrich Taegtmeyer; Fiscal Year: 2007
    ..abstract_text> ..
  26. Role of Caspase-9 in Heart
    Peter Kang; Fiscal Year: 2005
    ..Thus, the cardiac specific knockout of caspase-9 using Cre-loxP technology allows us to examine the tissue-specific role of capase-9 in adult animal. ..
  27. DYNAMICS OF MYOCARDIAL GLUCOSE METABOLISM
    Heinrich Taegtmeyer; Fiscal Year: 2002
    ....
  28. TRANSCRIPTIONAL CONTROL OF CARDIAC HYPERTROPHY
    Eric Olson; Fiscal Year: 2002
    ..End of Abstract) ..
  29. IGF-1, Oxidative Stress and Cardiovascular Aging
    Jun Ren; Fiscal Year: 2002
    ..Our long-term goal is to establish the causal link among IGF-1 deficiency, enhanced oxidative damage and ventricular dysfunction in the progression of cardiovascular aging so that hormonal or antioxidant therapy can be optimized...
  30. Laser Microdissection System
    Eric Olson; Fiscal Year: 2004
    ....
  31. MOLECULAR AND CELLULAR MECHANISMS OF HEART DISEASE
    Heinrich Taegtmeyer; Fiscal Year: 2003
    ..abstract_text> ..
  32. Signaling Pathways Mediating NCX1 Expression
    Donald Menick; Fiscal Year: 2004
    ..The therapeutic modulation of these targets may potentially reverse the endpoints associated with the disease phenotype. ..
  33. Gordon Research Conference:Cardiac Regulatory Mechanisms
    R Solaro; Fiscal Year: 2002
    ..Much of the time of the meeting is devoted to debates and discussion. Presentations of late breaking science from young investigator will be added from the posters submitted to the meeting. ..
  34. ISOLATED DIASTOLIC DYSFUNCTION
    MARGARET REDFIELD; Fiscal Year: 2008
    ....
  35. TRANSCRIPTIONAL CONTROL OF CARDIOVASCULAR PATHOLOGY
    Kenneth Walsh; Fiscal Year: 2001
    ....
  36. Mechanisms of Angiogenesis
    Kenneth Walsh; Fiscal Year: 2009
    ..LKB1-knockout mice will be created and their baseline phenotype will be assessed. Endothelial LKB1-deficient mice will be subjected to ischemic stresses and vascular responses will be evaluated. ..
  37. Vitamin D and Cardiovascular Disease
    Ravi Thadhani; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  38. COLLABORATIVE R01
    Rhonda Bassel Duby; Fiscal Year: 2002
    ..In this iterative manner, the investigators expect to gain knowledge that ultimately will foster the development of cell transplantation strategies to promote myocardial repair in human patients afflicted with heart failure. ..
  39. SPARC Modulates Extracellular Matrix Dynamics in Skin
    AMY BRADSHAW; Fiscal Year: 2004
    ....
  40. MOLECULAR PHYSIOLOGY OF MYOCARDIAL TROPONIN I VARIANTS
    Anne Murphy; Fiscal Year: 2008
    ..In the long-term this will assist in the development of novel therapies which address the correction of myofilament defects. ..
  41. MECHANISMS OF DILATED CARDIOMYOPATHY IN CREB A133
    Guy Reed; Fiscal Year: 2002
    ..Taken together the results of this work should provide us with important new insights into the molecular mechanisms underlying human DC and CHF. ..
  42. NATRIURETIC PEPTIDE INHIBITS VEGF SYNTHESIS AND ACTIONS
    ELLIS LEVIN; Fiscal Year: 2002
    ..These will be shown by protein synthesis and kinase activity studies, in cells transfected with dominant negative SEK-1 (JNK kinase) and JNK-1, or PD98059 (Mek inhibitor). ..
  43. The Effect of Statins on Skeletal Muscle Function
    PAUL DAVIS THOMPSON; Fiscal Year: 2010
    ....
  44. PO2 MODULATION OF NO AND ET1 IN PULMONARY HYPERTENSION
    Karen Fagan; Fiscal Year: 2002
    ..Improved understanding of these endogenous vasoregulatory substances, their interactions with one another, and the effect of modest hypoxia in vivo are the major goals of this proposal and may lead to new therapeutic options. ..
  45. ROLES FOR P38 MAP KINASES IN CARDIAC MYOCYTE GROWTH
    CHRISTOPHER GLEMBOTSKI; Fiscal Year: 2003
    ..abstract_text> ..
  46. RHOA KINASES IN CARDIAC HYPERTROPHY
    Robert Schwartz; Fiscal Year: 2003
    ..abstract_text> ..
  47. GENETIC ANALYSIS OF CARDIAC TERMINAL DIFFERENTIATION
    W MacLellan; Fiscal Year: 2003
    ..This first RO1 proposes to further define the role of PRI-1 in cardiac myocyte differentiation and elucidate its biochemical properties. ..
  48. SYSTOLIC CARDIAC FUNCTION IN OBESITY AND EXERCISE
    JOAN CARROLL; Fiscal Year: 2004
    ..Because such a large segment of the American population is overweight or obese, the knowledge and insight gained from these studies can have far-reaching effects. ..
  49. ANDROGENS, LIPIDS, INSULIN AND HYPERTENSIVE PREGNANCIES
    Ravi Thadhani; Fiscal Year: 2005
    ..abstract_text> ..
  50. Pulse Doppler Ultrasound Imaging System
    JOAN CARROLL; Fiscal Year: 2004
    ..abstract_text> ..
  51. MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW
    George Mansoor; Fiscal Year: 2004
    ..This study will provide information that will be important if clinical trials targeting nocturnal BP are to be designed. ..
  52. MECHANICAL REGULATION OF DILATED CARDIOMYOPATHY
    Jeffrey Omens; Fiscal Year: 2004
    ..We propose that these regional structural changes accompanies dilatory heart failure, and are mechanisms behind the reduction in fiber shortening and the ability of the wall to thicken during systole. ..
  53. Osteoblastogenesis in Aortic Valve Calcification
    Nalini Rajamannan; Fiscal Year: 2006
    ..If hypercholesterolemia stimulates the development of calcification in the aortic valve then the use of medical therapy such as HMG CoA reductase medications may have a role in the medical therapy of calcific aortic stenosis. ..
  54. Role of H11 kinase in cardiac cell growth
    Christophe Depre; Fiscal Year: 2007
    ..These experiments will unravel novel mechanisms and signaling pathways of cardiac growth, which may result in new therapeutic avenues for both ischemic heart disease and heart failure. ..
  55. Regulation of cardiac ion channel function via allosteric modulators
    Andrew Marks; Fiscal Year: 2007
    ..The studies are significant because they may lead to a novel therapeutic approach based on allosteric modulation of RyR that can result in improved therapy for human cardiovascular diseases. ..
  56. Cardiac KATP Channels in Health and Disease
    Andre Terzic; Fiscal Year: 2007
    ..Thus, this proposal will provide an integrated understanding of cardiac KATP channels in metabolic signal decoding, stress adaptation, and their impact for clinical medicine. ..
  57. Steroid As Cytoprotectants against Oxidative Toxicity
    Qin Chen; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  58. ECHOCARDIOGRAPHIC STROKE PREDICTORS IN A TRI-ETHNIC COMM
    Marco Di Tullio; Fiscal Year: 2003
    ..This study will be the first prospective cohort study to evaluate the role of multiple echocardiographic risk factors for ischemic stroke in a community of whites, blacks and Hispanics living in the same area. ..
  59. NF-kappaB Signaling Networks in I/R and Late PC
    W Jones; Fiscal Year: 2007
    ..abstract_text> ..
  60. Cardiac Contraction-Relaxation Coupling
    PAULUS JANSSEN; Fiscal Year: 2008
    ....
  61. Effect of Drugs on Myocardial Hypoxia
    Garrett Gross; Fiscal Year: 2009
    ..Information gained from these studies will hopefully lead to new therapies to treat patients with ischemic heart disease. ..
  62. The Role of Microsatellite Instability in Cancer
    Harold Garner; Fiscal Year: 2005
    ..We will also (Aim 3) investigate the effects of these mutations identified in Aim 2 on splicing by correlating them with the results of a quantitative global survey of splicing isoforms. ..
  63. Functional role of Angiopoietin-2 in diabetic heart
    Jian xiong Chen; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..